Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

The Lancet Oncology

Volumn 18, Issue 7, 2017, Pages 863-873

  Davies, Michael A ^a   Saiag, Philippe ^b,c   Robert, Caroline ^d   Grob, Jean Jacques ^e   Flaherty, Keith T ^f   Arance, Ana ^g   Chiarion Sileni, Vanna ^h   Thomas, Luc ⁱ   Lesimple, Thierry ^j   Mortier, Laurent ^k   Moschos, Stergios J ^l   Hogg, David ^m   Márquez Rodas, Iván ⁿ   Del Vecchio, Michele ^o   Lebbé, Céleste ^p   Meyer, Nicolas ^q   Zhang, Ying ^r   Huang, Yingjie ^r   Mookerjee, Bijoyesh ^r   Long, Georgina V ^s  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HÔPITAL AMBROISE PARÉ   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e TIMONE HOSPITAL   (France)

^f MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^g HOSPITAL CLÍNIC   (Spain)

^h VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

ⁱ CENTRE HOSPITALIER LYON SUD   (France)

^j CENTRE EUGÈNE MARQUIS   (France)

^k LILLE UNIVERSITY HOSPITAL   (France)

^l UNIVERSITY OF NORTH CAROLINA   (United States)

^m PRINCESS MARGARET HOSPITAL   (Canada)

ⁿ HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^o NATIONAL CANCER INSTITUTE   (Italy)

^p SAINT LOUIS HOSPITAL   (France)

^q La Croix du Sud Hospital   (France)

^r NOVARTIS PHARMA AG   (Switzerland)

^s UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DABRAFENIB; TRAMETINIB; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; OXIME; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BACKACHE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CHILL; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COHORT ANALYSIS; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRY SKIN; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEART EJECTION FRACTION; HUMAN; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; MYALGIA; NAUSEA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; VOMITING; AGED; BRAIN NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG EFFECTS; GENETICS; HEADACHE; HEART STROKE VOLUME; MIDDLE AGED; MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSPECTIVE STUDY; SECONDARY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; FEMALE; FEVER; HEADACHE; HUMANS; IMIDAZOLES; MAGNETIC RESONANCE IMAGING; MALE; MELANOMA; MIDDLE AGED; MUTATION; OXIMES; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; STROKE VOLUME; YOUNG ADULT;

EID: 85020120926     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30429-1     Document Type: Article

References (28)

1. Cohen, JV, Tawbi, H, Margolin, KA, et al. Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell Melanoma Res 29 (2016), 627–642.
2. Sampson, JH, Carter, JH Jr, Friedman, AH, Seigler, HF, Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88 (1998), 11–20.
3. Long, GV, Margolin, KA, Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies. Am Soc Clin Oncol Educ Book, 2013, 393–398.
4. Davies, MA, Liu, P, McIntyre, S, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117 (2011), 1687–1696.
5. Raizer, JJ, Hwu, WJ, Panageas, KS, et al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol 10 (2008), 199–207.
6. Long, GV, Stroyakovskiy, D, Gogas, H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386 (2015), 444–451.
7. Robert, C, Karaszewska, B, Schachter, J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372 (2015), 30–39.
8. Larkin, J, Chiarion-Sileni, V, Gonzalez, R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
9. Robert, C, Schachter, J, Long, GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372 (2015), 2521–2532.
10. Ascierto, PA, McArthur, GA, Dreno, B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17 (2016), 1248–1260.
11. Long, GV, Trefzer, U, Davies, MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13 (2012), 1087–1095.
12. Margolin, K, Ernstoff, MS, Hamid, O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13 (2012), 459–465.
13. Goldberg, SB, Gettinger, SN, Mahajan, A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17 (2016), 976–983.
14. Flaherty, KT, Infante, JR, Daud, A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367 (2012), 1694–1703.
15. Long, GV, Weber, JS, Infante, JR, et al. Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol 34 (2016), 871–878.
16. Long, GV, Stroyakovskiy, D, Gogas, H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371 (2014), 1877–1888.
17. Long, GV, Flaherty, KT, Stroyakovskiy, D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol, 2017, 10.1093/annonc/mdx176 published online May 5.
18. Robert, C, Karaszewska, B, Schachter, J, et al. Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. Eur J Cancer, 51(suppl 3), 2015, S663 (abstr 3301).
19. Robert, C, Karaszewska, B, Schachter, J, et al. Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. Ann Oncol 27:suppl 6 (2016), 552–587 (abstr LBA40).
20. Fife, KM, Colman, MH, Stevens, GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22 (2004), 1293–1300.
21. Dummer, R, Goldinger, SM, Turtschi, CP, et al. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 50 (2014), 611–621.
22. Haanen J, Hwu W, Martín-Algarra S, et al. Efficacy and safety of nivolumab (NIVO) alone or combined with ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain in a phase 1 study. Society for Melanoma Research Thirteenth International Congress; Boston, MA; Nov 6–9, 2016.
23. Tawbi H, Algazi A, Forsyth P, et al. Safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with advanced melanoma (MEL) metastatic to the brain: initial results from phase 2 CheckMate 204. Society for Melanoma Research Thirteenth International Congress; Boston, MA; Nov 6–9, 2016.
24. Long, GV, Atkinson, V, Menzies, AM, et al. A randomized phase 2 study of nivolumab and nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases: the Anti-PD1 Brain Collaboration (ABC Study). J Clin Oncol, 34(suppl), 2016 abstr TPS9591.
25. Long, GV, Grob, J, Nathan, P, et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol 17 (2016), 1743–1754.
26. Chen, G, Chakravarti, N, Aardalen, K, et al. Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res 20 (2014), 5537–5546.
27. Niessner, H, Forschner, A, Klumpp, B, et al. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med 2 (2013), 76–85.
28. Amaral, T, Sinnberg, T, Meier, F, et al. The mitogen-activated protein kinase pathway in melanoma part I—activation and primary resistance mechanisms to BRAF inhibition. Eur J Cancer 73 (2017), 85–92.